High pressure Shot Cell Disruptor

The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition to Constant Systems LTD for the procurement of a high-pressure shot cell disruptor. The device will be used for protein purification and characterization studies involving membrane proteins. The NIH requires a high-pressure homogenization system capable of providing controlled, reproducible cell disruption while maximizing sample recovery and minimizing processing-related damage. • The contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01. • The acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). • Interested parties may identify their interest and capability to respond to this notice, but the Government may still proceed on a non-competitive basis.